Want to see HLN full AI Analyst Report?
Top Page
Haleon PLC Sponsored ADR
(NYSE:HLN)
Select Model
Select Model
Rating:68Neutral
Price Target:
$11.00
▲(12.47% Upside)
Action:Reiterated
Date:08/06/26
HLN scores in the upper-middle range driven primarily by improving profitability and solid cash generation, with leverage trending better but still a constraint amid recent revenue softness. Technicals add modest support (price above key moving averages with a positive MACD, but only moderate momentum). Valuation is reasonable rather than cheap, and the latest earnings call supports the outlook with reiterated 3–5% guidance and ongoing cost/margin initiatives, tempered by near-term U.S./cold & flu and volume headwinds.
Positive Factors
Margin expansion & cash conversion
Sustained gross margin improvement and very high cash conversion materially strengthen earnings quality. With free cash flow near reported earnings, the business can internally fund A&P, R&D and de‑leveraging, improving balance sheet resilience and funding flexibility over coming quarters.
Negative Factors
Top‑line softness and weak volume trends
Low volume growth and recent revenue softness blunt operating leverage and make organic expansion harder to sustain. Weak unit momentum constrains long‑term sales growth, limits pricing power in some categories, and raises execution risk for medium‑term targets absent clear volume recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin expansion & cash conversion
Sustained gross margin improvement and very high cash conversion materially strengthen earnings quality. With free cash flow near reported earnings, the business can internally fund A&P, R&D and de‑leveraging, improving balance sheet resilience and funding flexibility over coming quarters.
Read all positive factors
Haleon PLC Sponsored ADR Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which may need strategic adjustments.
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyHaleon PLC Sponsored ADR (HLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.65B
Dividend Yield1.28%
Average Volume (3M)8.96M
Price to Earnings (P/E)19.5
Beta (1Y)0.13
Revenue Growth4.99%
EPS Growth12.37%
CountryUS
Employees24,535
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.36
Shares Outstanding4,404,513,000
10 Day Avg. Volume8,681,907
30 Day Avg. Volume8,956,540
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio17.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.61Price Target Upside-11.99% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.56
Revenue Forecast (FY)$15.30B
Haleon PLC Sponsored ADR Business Overview & Revenue Model
Company Description
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extend...
How the Company Makes Money
Haleon primarily makes money by selling branded consumer health products to retailers, wholesalers, pharmacies, and e-commerce platforms, generating revenue when these customers purchase Haleon’s products for resale to end consumers. Its key reven...
Haleon PLC Sponsored ADR Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 04, 2027
Earnings Call Sentiment Positive
The call conveyed more positive than negative developments: solid organic growth (3.1%) with sequential improvement, robust margin expansion (gross margin +140 bps; operating margin +120 bps), strong region/product performances (Oral Care, China, India, emerging markets) and continued investment behind digital and innovation. Key headwinds—weak Respiratory (notably cough & cold), regional softness in Europe and the Middle East, and some pricing pressure in Asia—are material but portrayed as cyclical or manageable through productivity and targeted reinvestment. Management maintained guidance (3%–5% organic growth) and expressed confidence in a stronger H2.Positive Updates
Organic sales growth and sequential improvement
Organic sales growth of 3.1% in Q2, a sequential improvement from Q1 (2.2%), with volume/mix contributing 1.4%.
Negative Updates
Respiratory health weakness
Respiratory Health was weak in Q2 and reportedly shaved ~150 basis points off organic sales growth; cough & cold (notably Contac in China) showed very little pickup and Smoker's Health continued to decline (though rate slowed).
Read all updates
Q2-2026 Updates
Positive
Negative
Organic sales growth and sequential improvement
Organic sales growth of 3.1% in Q2, a sequential improvement from Q1 (2.2%), with volume/mix contributing 1.4%.
Read all positive updates
Company Guidance
Management reiterated FY26 organic sales guidance of 3–5% (while maintaining a medium‑term ambition of 4–6%) and said H2 should be stronger than H1; Q2 organic sales were 3.1% (Q1 2.2%) with overall volume mix +1.4% and North America volume +2%, A&P in H1 grew 3.2% and sits at ~20.9% of sales with a planned step‑up in H2, and pricing is described as broadly in line with inflation and expected to be similar in H2. On margins, H1 constant‑currency operating margin improved 120 bps (gross margin +140 bps; FX +40 bps) and the company expects to deliver high‑single‑digit operating margin growth in H2, continue gross‑margin improvement while absorbing Middle East contract/hedge cost roll‑offs without exceptional pricing, and drive continued strong EPS growth after H1 EPS rose ~12%. They also reconfirmed operating‑model savings of GBP 175–200m in total, with roughly one‑third expected to fall in the current year.Haleon PLC Sponsored ADR Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
63
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.16B | 11.03B | 11.23B | 11.30B | 10.86B | 9.54B |
| Gross Profit | 7.31B | 6.99B | 6.95B | 6.96B | 6.58B | 5.95B |
| EBITDA | 2.95B | 2.88B | 2.51B | 2.35B | 2.18B | 2.21B |
| Net Income | 1.62B | 1.63B | 1.44B | 1.05B | 1.06B | 1.39B |
Balance Sheet | ||||||
| Total Assets | 32.38B | 32.57B | 34.31B | 34.05B | 34.81B | 34.45B |
| Cash, Cash Equivalents and Short-Term Investments | 821.01M | 1.32B | 2.25B | 1.04B | 684.00M | 414.00M |
| Total Debt | 8.20B | 8.59B | 10.10B | 9.46B | 10.44B | 991.00M |
| Total Liabilities | 16.04B | 16.12B | 18.09B | 17.33B | 18.36B | 7.97B |
| Stockholders Equity | 16.28B | 16.40B | 16.17B | 16.61B | 16.33B | 26.36B |
Cash Flow | ||||||
| Free Cash Flow | 2.05B | 1.97B | 2.05B | 1.76B | 1.74B | 1.06B |
| Operating Cash Flow | 2.39B | 2.29B | 2.30B | 2.10B | 2.06B | 1.36B |
| Investing Cash Flow | -386.95M | -567.29M | 528.00M | -134.00M | -8.78B | -33.00M |
| Financing Cash Flow | -1.87B | -2.55B | -1.54B | -1.57B | 6.91B | -1.24B |
Haleon PLC Sponsored ADR Technical Analysis
Positive
9.78
Price Trends
9.57
Positive
9.50
Positive
9.74
Positive
Market Momentum
0.06
Positive
48.72
Neutral
41.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLN, the sentiment is Positive. The current price of 9.78 is below the 20-day moving average (MA) of 9.95, above the 50-day MA of 9.57, and above the 200-day MA of 9.74, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 48.72 is Neutral, neither overbought nor oversold. The STOCH value of 41.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HLN.
Haleon PLC Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $43.18B | 56.52 | 9.28% | ― | 4.33% | ― | |
68 Neutral | $42.65B | 19.52 | 9.89% | 1.97% | 4.99% | 12.37% | |
62 Neutral | $10.52B | 30.21 | 8.88% | 0.95% | -6.76% | -44.33% | |
60 Neutral | $55.69B | 49.12 | 2.40% | 3.61% | -0.14% | -208.74% | |
59 Neutral | $18.42B | -45.08 | -2.79% | 2.78% | 4.92% | 87.81% | |
54 Neutral | $1.78B | -1.04 | -55.97% | 11.50% | -4.18% | -2138.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HLN
Haleon PLC Sponsored ADR
9.70
0.23
2.44%
RDY
Dr Reddy's Laboratories
12.27
-1.87
-13.24%
VTRS
Viatris
16.23
6.02
59.01%
PRGO
Perrigo Company
13.04
-7.87
-37.65%
TEVA
Teva Pharmaceutical
36.77
18.91
105.88%
TAK
Takeda Pharmaceutical Company
17.63
2.63
17.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.